Cortagen
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
Cortagen is a synthetic tetrapeptide — a short chain of four amino acids (alanine, glutamic acid, aspartic acid, and proline, often written AEDP). It was developed within the Russian “peptide bioregulator” research program as a compact analog reflecting an active component of natural brain-cortex peptide preparations such as cortexin.
It is most often discussed in the context of the nervous system, where it has been studied for neuroprotection, cognitive function, and nerve regeneration. Because of its very small size, it is grouped with the ultrashort peptides investigated by Khavinson and colleagues.
Most of the available evidence comes from preclinical animal and cell studies, much of it published in Russian-language literature. Human clinical data is limited, and Cortagen is not approved by major Western regulators for therapeutic use.
How it works
The proposed mechanism for Cortagen and related short peptides is epigenetic regulation of gene expression. Researchers hypothesize that these small peptides can cross cell and nuclear membranes, interact with specific DNA regions, and influence how genes are switched on or off — potentially supporting the production of proteins involved in maintaining neuronal function.
In preclinical models this activity has been associated with a neuroprotective and regenerative signature. In one animal study of sciatic-nerve injury, Cortagen was reported to increase the growth rate and conduction velocity of regenerating nerve fibers relative to controls. The precise mechanism in humans has not been established.
Reported benefits
- Neuroprotection and support for neuronal function (preclinical data)
- Support for peripheral nerve regeneration after injury (animal models)
- Cognitive and CNS support, framed as an area of emerging research
These are reported and studied effects from mostly preclinical work, not guaranteed outcomes.
Considerations & side effects
Because rigorous human trials are lacking, the safety profile of Cortagen is not well characterized, and long-term effects in people are not established. Published preclinical reports describe it as generally well tolerated, but this does not substitute for human safety data.
Product purity and identity vary widely in the research-chemical market, and material sold for “research use only” is not manufactured to pharmaceutical standards in most countries. Cortagen is not a substitute for evaluation and treatment by a qualified clinician.
Frequently asked
What is Cortagen?
Cortagen is a synthetic tetrapeptide (the sequence Ala-Glu-Asp-Pro, or AEDP) developed from analysis of natural brain-cortex peptide preparations. It belongs to the family of short 'bioregulator' peptides studied for effects on the nervous system.
Is Cortagen FDA-approved?
No. Cortagen is not approved by the FDA or other major Western regulators for human therapeutic use and is generally sold for research purposes only, though it has been registered as a bioregulator preparation in Russia.
What is Cortagen studied for?
Most published research is preclinical and focuses on neuroprotection, cognitive function, and peripheral nerve regeneration in animal models. Human clinical evidence is limited.
How is Cortagen related to cortexin?
Cortagen was designed as a short synthetic peptide reflecting an active fraction of cortexin, a natural brain-cortex peptide complex studied in Russian bioregulation research.
References
Related compounds
An oral Khavinson peptide bioregulator (peptide complex A-5) derived from calf brain tissue, targeting the central nervous system. Taken in capsule courses to support cognitive function and neuronal health.
Standardized neuropeptide preparation with neurotrophic and neuroprotective properties. Used clinically in 50+ countries for stroke recovery, traumatic brain injury, and dementia treatment.
Small peptide derived from angiotensin IV. Potent cognitive enhancer that promotes synaptic connectivity via HGF/MET signaling. Highly experimental with limited human data.